) is deregulated in cancer. Despite this fact, it is not currently known how tRNA i
Met expression levels influence tumor progression. We have found that tRNA i Met expression is increased in carcinoma-associated fibroblasts, implicating deregulated expression of tRNA i
Met in the tumor stroma as a possible contributor to tumor progression. To investigate how elevated stromal tRNA i Met contributes to tumor progression, we generated a mouse expressing additional copies of the tRNA i Met gene (2+tRNA i Met mouse). Growth and vascularization of subcutaneous tumor allografts was enhanced in 2+tRNA i
Met mice compared with wild-type littermate controls. Extracellular matrix (ECM) deposited by fibroblasts from 2+tRNA i Met mice supported enhanced endothelial cell and fibroblast migration. SILAC mass spectrometry indicated that elevated expression of tRNA i Met significantly increased synthesis and secretion of certain types of collagen, in particular type II collagen. Suppression of type II collagen opposed the ability of tRNA i Met -overexpressing fibroblasts to deposit pro-migratory ECM. We used the prolyl hydroxylase inhibitor ethyl-3,4-dihydroxybenzoate (DHB) to determine whether collagen synthesis contributes to the tRNA i Met -driven pro-tumorigenic stroma in vivo. DHB had no effect on the growth of syngeneic allografts in wild-type mice but opposed the ability of 2+tRNA i Met mice to support increased angiogenesis and tumor growth. Finally, collagen II expression predicts poor prognosis in high-grade serous ovarian carcinoma. Taken together, these data indicate that increased tRNA i Met levels contribute to tumor progression by enhancing the ability of stromal fibroblasts to synthesize and secrete a type II collagen-rich ECM that supports endothelial cell migration and angiogenesis.
INTRODUCTION
The use of transcriptomics and proteomics to understand cellular function has been pivotal in advancing our knowledge of the molecular basis of disease processes, and the combined use of these approaches is beginning to highlight discord between the control of gene expression at the levels of transcription and translation. Indeed, implementation of numerous post-transcriptional processes means that expression of particular genes at the mRNA level does not necessarily correlate with cellular concentrations of functional products of the same transcripts. tRNAs are one of the most-abundant RNAs in eukaryotic cells, yet are frequently disregarded in most genome-wide analyses because they are assumed to be background genes with merely housekeeping functions. However, it is now becoming clear that cellular levels of tRNAs are key to the control of gene expression in a number of different contexts. Indeed, tissue-specific differences in tRNA expression occur across a variety of human tissues, with relative levels of tRNAs correlating to the codon usage of highly expressed genes in those tissues [1] . Indeed, the availability of certain tRNAs may be controlled in the cell in order to regulate the efficiency of translation of certain gene transcripts. This may, in turn, allow the cell to regulate the activity of certain pathways [2] . For instance, proliferating cells have increased levels of tRNAs that are specific for codons overrepresented in pathways required for proliferation. A number of publications have demonstrated that tRNA levels may be increased in cancer [3] [4] [5] , and although it was previously unknown whether this was a cause or consequence of carcinogenesis, recent work from Gingold et al. [2] highlighted the possibility that tRNA expression could indeed play a role in carcinogenesis itself.
There has also been some focus on the consequences of altered expression of specific tRNAs, including tRNA i Met , the initiator methionine tRNA responsible for recognizing the start codon and initiating translation. Whereas one group indicated that overexpression of tRNA i Met may reprogram global tRNA expression levels and increase proliferation of human epithelial cells [6] , another showed that increased levels of tRNA i Met influences the growth of Drosophila larvae largely owing to increased secretion of insulin-related peptides from fat bodies [7] . This in vivo observation that tRNA i Met levels can drive protein secretion is particularly interesting. It indicates that tRNA i Met -sensitive translational control may contribute to cancer progression not only by altering gene expression of the cancer cells themselves but also by altering the secretome of other cells that support carcinogenesis [8] [9] [10] .
In the current study, we find that levels of tRNA i Met are increased in cancer-associated fibroblasts (CAFs) by comparison to normal fibroblasts. To further understand the consequences of altered stromal expression of tRNA i Met , we generated a transgenic mouse that carries two additional copies of the tRNA i Met gene (2+tRNA i Met mouse). We found that this leads to enhanced tumor growth and enhanced tumor vascularization.
In terms of mechanism, we show that increased tumor growth in 2+tRNA i Met mice is due to elevated secretion of type II collagen by fibroblasts which, in turn, supports migration of endothelial cells, leading to increased tumor vascularity. Our data therefore provide the first evidence that tRNA i Met levels selectively drive secretion of specific components of the extracellular matrix (ECM) to support tumor progression.
RESULTS

Increased Expression of tRNA i Met in the Host Animal
Promotes Tumor Growth and Angiogenesis To determine whether tRNA expression is altered in the tumor stroma, we measured tRNA levels in immortalized human mammary carcinoma-associated fibroblasts (iCAFs) and compared these with immortalized matched normal fibroblast (iNF) controls. iCAFs were generated by co-injecting iNFs with Ras-transformed MCF7 cells subcutaneously into mice [11] . These iCAFs are established to have an enhanced capacity to promote tumor growth and angiogenesis when co-injected as xenografts with a variety of tumor cell types and are established to maintain their myofibroblast-like phenotype when grown in culture [11] . We characterized these cells for the expression of non-coding RNA transcribed by RNA polymerase III. Importantly, increased expression of tRNA i Met and the tRNA for isoleucine (tRNA Ile ) was seen in iCAFs by comparison with iNFs, whereas no change was detected in the expression of the 5S rRNA, another noncoding RNA transcribed by RNA polymerase III ( Figure S1 ).
To investigate the consequences of increased stromal tRNA i
Met , we generated a transgenic mouse that carries two extra copies of the tRNA i Met gene inserted into the genome at the HPRT locus (2+tRNA i Met mouse; Figure S2A ). 2+tRNA i Met animals have elevated levels (1.3-to 1.5-fold) of tRNA i Met in a number of tissues, including fibroblasts from lung and from whole-mouse embryos (MEFs) ( Figure S2B Figure S2B ) and used these to prepare cell-derived matrices using established methods [13, 14] . We then investigated the capacity of this cell-free ECM to support the migration of other cells. ECM deposited by primary cultured fibroblasts from 2+tRNA i Met mice had significantly enhanced ability to support migration of both endothelial cells ( Figure 2A ) and fibroblasts ( Figure 2B ) by comparison with ECM deposited by cells from their wildtype littermate controls. As a tool to determine how increased tRNA i Met expression influences ECM deposition, we generated independent pools of immortalized mouse embryonic fibroblasts (iMEF) transfected with either tRNA i Met (iMEF-tRNA i Met ) or an empty vector control (iMEF-vector) ( Figure S3A ). Consistent with our observations in primary cultured MEFs, increased tRNA i
Met expression did not lead to increased cell proliferation or cellular protein synthesis in immortalized MEFs ( Figures S3B  and S3C ). However, ECM deposited by iMEF-tRNA i Met cells had a similarly enhanced ability to support increased cell migration as did the ECM secreted by primary cultured fibroblasts from 2+tRNA i Met mice ( Figure 3A ).
To determine whether the relationship between tRNA i Met expression and the deposition of pro-migratory ECM was observable in fibroblasts from human tumors, we obtained primary CAFs from two human breast tumors and compared these with fibroblasts isolated from the surrounding normal tissue (>5 cm from the tumor) from the same patients. The CAFs from patient 1 displayed significant upregulation of tRNA i Met by comparison with fibroblasts from surrounding normal tissue, but this was not observed in the second patient (patient 2) (Figure S4A) . Interestingly, the ECM produced by CAFs from patient 1 supported significantly increased cell migration, whereas the CAF-derived ECM from patient 2 did not ( Figure S4B ). These data indicate that, although upregulation of tRNA i Met in CAFs varies between patients, the relationship between tRNA i Met levels and the ability to generate pro-migratory ECM may be observed in primary cultured CAFs from human tumors. Many ECM components are initially secreted by fibroblasts as soluble proteins that are subsequently incorporated into the insoluble ECM. To determine which of these stages of ECM deposition are influenced by tRNA i
Met levels, we collected conditioned medium from iMEF-tRNA i Met and iMEF-vector cells and incubated these with normal iMEFs, which were, in turn, allowed to deposit ECM. Interestingly, ECM deposited by iMEFs cultured in conditioned medium from tRNA i Met -overexpressing cells had significantly enhanced ability to support cell migration ( Figure 3B ), indicating that tRNA i Met levels control the synthesis and secretion of soluble ECM components rather than the ability of fibroblasts to remodel these and incorporate them into insoluble ECM.
Cell migration may be influenced by the mechanical properties of the ECM. ECM stiffness promotes cell migration, and certain secreted enzymes (such as lysyl oxidases and transglutaminases) catalyze the formation of covalent cross-links between amino acid chains to increase ECM stiffness. We used atomic force microscopy (AFM) to measure the mechanical properties of ECM and found that cell-derived matrix generated in the presence of conditioned medium from tRNA i Met -overexpressing cells did not consistently differ in its thickness or stiffness from that generated in the presence of conditioned medium from control cells ( Figure 3C ). Taken together, these data indicate that increased tRNA i Met expression supports deposition of a promigratory ECM via release of secreted components that do not influence the mechanical properties of the ECM.
Increased tRNA i Met Levels Drive a Secretome that Is Enriched in Type II Collagen
We used SILAC-based mass spectrometry to quantitatively determine the influence of tRNA i Met levels on the complement of soluble proteins secreted by fibroblasts. We labeled iMEFtRNA i Met and iMEF-vector cells with light and heavy SILAC amino acids, respectively (forward [Fw] labeling), and with heavy and light amino acids, respectively (reverse [Rev] labeling). We then prepared cell extracts, and for the secretome, we used an affinity bead (Strataclean)-based approach to enrich for proteins secreted into serum-free conditioned medium [15] . Proteomes were detected using an LTQ-Orbitrap, and mass spectrometry data were analyzed with the MaxQuant computational platform, which identified proteins in the proteome and in the secretome (Tables S1 and S2 ) with high correlation between Fw and Rev experiments. Analysis of the cellular proteome indicated that increased tRNA i Met levels disproportionately increased the synthesis of proteins destined for secretion ( Figure 4A ; Table  S1 ) whereas not greatly affecting the production of cellular non-secreted components. By contrast, the composition of the secretome was significantly altered by increased expression of tRNA i Met ( Figures 4B and 4C) . Indeed, tRNA i Met overexpression lead to enhanced production of many secreted ECM components, including collagens and collagen-processing enzymes ( Figure 4C ). In particular, type II collagen secretion by fibroblasts was upregulated by at least 50-fold following tRNA i Met overexpression in these cells (Figures 4B and 4C; Table S2 ). Furthermore, specificity in the nature of the secreted ECM components was observed in iMEF-tRNA i Met cells, which did not necessarily correlate with protein abundance ( Figure 4D ). For example, despite the observation that fibronectin was one of the mostabundant proteins in the secretome, its levels were not significantly altered following tRNA i Met overexpression ( Figures 4C   and 4D ). Upregulated expression of a given protein is commonly associated with increased recruitment of its mRNA(s) to actively translating ribosomes (polysomes). We used sucrose density gradients to determine whether increased tRNA i Met levels were able to drive polysomal recruitment of collagen II mRNA. We found no indication that the monosome/polysome ratio differed between iMEF-vector and iMEF-tRNA i Met cells ( Figure S5A ), which is consistent with our observations that the overall levels of cellular protein synthesis were unaffected by increased tRNA i Met levels ( Figures S2C and S3C) . However, iMEF.tRNA i Met cells displayed markedly increased polysomal content of collagen II mRNA ( Figure S5B ). Conversely, polysomal association of mRNAs for fibronectin and the ARPP0 ribosomal protein with polysomes was unaffected by increased tRNA i Met levels ( Figures S5C and S5D) . Immunostaining of ECM deposited by two independent tRNA i Met -overexpressing cell lines confirmed that upregulation of soluble secreted type II collagen was also reflected by its Figures 6A and S6A-S6C) . Furthermore, knockdown of type II collagen (with two independent siRNA sequences) in primary lung fibroblasts isolated from 2+tRNA i Met mice similarly compromised the ability of the ECM derived from these cells to support increased migration of endothelial cells ( Figure 6B) .
ECM was also made from iMEFs in which type II collagen levels had been suppressed using CRISPR genome editing (MEF-tRNA i Met /collagen II CRISPR; Figures S6D and S6E ). Immunostaining indicated significantly decreased type II collagen incorporation into ECM deposited by MEF-tRNA i Met /collagen II CRISPR cells ( Figure 6C, left panel) . Consistently, ECM generated by MEF-tRNA i Met /collagen II CRISPR fibroblasts had decreased ability to support increased cell migration ( Figures  6C, right panel, and S6F ). We then determined whether collagen synthesis was required for generation of a pro-tumorigenic microenvironment in vivo. To do this, we used ethyl-3,4-dihydroxybenzoate (DHB), a prolyl hydroxylase inhibitor that is well-established to compromise collagen processing in vivo and thus prevents collagen secretion in vivo [16] . Indeed, DHB administration significantly reduced the collagen II content of allografted tumors in both wild-type and tRNA i Met mice (Figures 5A and 5B) . However, whereas DHB treatment did not affect vascularity or growth of LLC subcu- (C) Atomic force microscopy and contact imaging were performed using a JPK NanoWizard II Bio AFM in combination with a Bruker MLCT cantilever and to measure the thickness of ECM following wound scratch or a Nanoworld Arrow TL-1 cantilever with bead attached for force spectroscopy; n = 3 independent ECM generations; ±SEM; ****p < 0.0001; ns, no significant difference; Kruskal-Wallis test.
taneous allografts in WT mice, it significantly opposed the increased vascularity and growth of tumors seen in 2+tRNA i Met mice ( Figure 5C ), indicating that collagen production is indeed required for tRNA i Met to drive tumor growth and angiogenesis in vivo.
Type II Collagen Expression Predicts Poor Prognosis in Ovarian Cancer
To determine whether the relationship between increased collagen II levels and tumor progression is observable in human cancer, we stained a tissue microarray containing 62 cases of primary ovarian tumors. The decision to focus on this cancer type was influenced by reports that ovarian cancer aggressiveness is particularly associated with increased angiogenesis [17] . In univariate analysis, high collagen II histoscores were associated with significantly decreased survival following resection of primary ovarian tumors (Figure 7) , and this was particularly apparent in high-grade serous carcinoma ( Figure S7 ). Indeed, patients with tumors displaying a collagen II histoscore greater than 50 have a 2.992-fold increased hazard ratio for death (p = 0.0002). These data indicate that collagen II expression is a significant factor in driving the progression of ovarian cancer.
DISCUSSION
Regulation of the cellular tRNA repertoire is thought to dictate selectivity of translational programs to influence cancer progression and to define cell fates [2] . Indeed, the tRNA repertoire differs between proliferating and differentiated cells, and this is thought to influence the translational landscape according to codon usage [2, 18] . Thus, an mRNA with a preponderance of a given codon will be translated more rapidly if the tRNA recognizing that codon is abundant. Consequently, one might anticipate that increased tRNA i Met (which recognizes AUG at translation start sites) would generally increase translation initiation and globally upregulate protein synthesis and cell growth [6] . However, our transgenic approach has given no indications that increased tRNA i Met levels promote cell growth or proliferation in a cell-autonomous fashion, nor does this greatly influence the quantity or profile of cellular protein synthesis. Instead, we have found that increased levels of tRNA i Met lead to highly selective adjustments to the protein synthesis landscape that are restricted to certain secreted proteins-particularly the ECM component, type II collagen. There is evidence from studies in Drosophila that elevated tRNA i Met controls production of secreted proteins. Introduction of one extra copy of the tRNA i Met gene into flies is sufficient to markedly enhance larval growth [7] . Consistent with our findings, this is primarily not attributable to a cell-autonomous drive to cell growth and proliferation in the developing organs. Rather, growth is driven by an endocrine relay in which increased tRNA i Met in fat body cells promotes secretion of factor(s) that trigger release of insulinlike peptides from brain neurosecretory cells that, in turn, circulate throughout the larvae to promote growth of developing organs and tissues [7] . ECM production constitutes a significant commitment to the cell (both in terms of load on the ER and the biosynthetic machinery), indicating the need for special mechanisms to be in place to control the translation of ECM proteins and other abundant components of the fibroblast secretome. Expression of type I collagens is known to be controlled at the level of mRNA stability and translation, due to unique 5 0 stem loops in their 5 0 UTRs [19] , and the production of these fibrillar collagens by the stroma is established to influence cancer growth and metastasis [20, 21] . Type II collagen is also a fibrillar collagen; however, little is known about how its production might be controlled post-transcriptionally. Although the sensitivity of collagen II production to tRNA i Met levels indicates that translation initiation is likely a key point of control of type II collagen synthesis, there are indications that the mechanism for this might not be straightforward. Indeed, in some cells (including those used for the polysome analysis displayed in Figure S5 ), we find that tRNA i Met overexpression increases the cellular levels of mRNA for type II collagen (not shown), indicating that tRNA i Met levels may influence transcription or stability of mRNAs for ECM proteins. Thus, despite clear indications that tRNA i Met levels selectively control ECM protein synthesis in a way that influences tumor outcomes, further work will be needed to fully establish the molecular mechanisms through which tRNA i Met levels influence type II collagen synthesis and the contribution made by the translational machinery to this non-cell-autonomous drive to tumor progression.
Despite the presence of a number of tRNA i Met -sensitive components in the fibroblast secretome, it is clear that suppression of just one of these, type II collagen, is sufficient to negate the tRNA i Met phenotype. Moreover, we have shown that stromal levels of type II collagen are strongly associated with aggressiveness of serous ovarian carcinoma, indicating the importance of this tRNA i Met -sensitive secreted factor to the progression of a human cancer type. However, we have been unable to quantitatively determine tRNA i Met levels in human tumor microarrays, and it will be necessary to do this to conclusively determine whether stromal tRNA i Met drives type II collagen synthesis in human tumors in the same way as we have demonstrated by performing allografts in our 2+tRNA i Met mouse model. Type II collagen is an abundant component of cartilage and is produced in large quantities by chondrocytes. By contrast, normal fibroblasts are not thought to secrete collagen II, and consistently, our SILAC data show that this collagen is a relatively minor component of the fibroblast secretome. Thus, acquisition of type II collagen secretion when tRNA i Met levels are increased may represent a shift to a more-chondrocyte-like phenotype, and this may be consistent with the role for the tRNA repertoire in influencing differentiation state [2] . In view of this, one might anticipate that increased tRNA i Met levels may be associated with production of ECM with cartilaginous features, such as increased stiffness. However, our AFM data show clearly that ECM produced by fibroblasts with increased tRNA i Met levels does not have consistently altered compliance, indicating that type II collagen content is not necessarily linked to stiffness. In addition to providing mechanical support, a key role of the ECM is to act as a reservoir for growth factors and other bioactive proteins. The tRNA i Met secretome contains a number of pro-tumorigenic growth factors (such as frizzledrelated protein and TGF-b2), and we are currently considering the possibility that type II collagen production is associated with secretion of these growth factors and their incorporation into the ECM, increasing their presentation to tumor and endothelial cells. . Incorporation of collagen II into the ECM was assessed by immunostaining using type-IIcollagen-specific antibodies, quantified using the Aerius infrared imaging system (LI-COR Biosciences); unpaired t test; *p < 0.05; **p < 0.005. Migration of iMEFs was recorded as previously described. Data represent ECM generated from at least three independent ECM isolations, tracking the migration of at least 40 iMEFs in each replicate. Box and whisker plot represents 5-95 percentile; Kruskal-Wallis test; ****p < 0.0001; ns, not significant. See Figures S6D-S6F for a schematic representation of the protocol for this experiment, the validation of the CRISPR, and representative examples of the migration track plots.
Targeting the translational initiation machinery with drugs has been shown to have sufficiently selective effects on protein synthesis in tumor cells to influence cancer progression. Indeed, eIF4A, which is the molecular target for the promising anticancer agent silvestrol, favors translation of key oncoproteins such as Myc, Notch, and BCL2 [22] . Our findings indicate that control of tRNA i Met levels in stromal fibroblasts is key to the generation of a collagen-II-rich pro-tumorigenic microenvironment, and this will provide further impetus to the search for drugs to manipulate translation initiation and ECM synthesis in cancer.
Our data also have implications for understanding the mechanisms of tumor angiogenesis. Although stromal fibroblasts are known to contribute to angiogenesis in tumors, the mechanisms through which fibroblasts promote tumor angiogenesis are incompletely understood [23] . The data presented here suggest that the secretion of a pro-migratory ECM by stromal fibroblasts is an important mechanism via which stromal fibroblasts promote angiogenesis in cancer. See Figure S7 for Kaplan-Meier analysis of the relationship between collagen II levels in the highgrade serous subset of these tumors.
with 10% FBS, 200 mM L-glutamine, 100 U/ml penicillin streptomycin, 0.25 mg/ml Fungizone, and 50 mM b-mercaptoethanol. Cells were cultured on 0.1% gelatin-coated plates and used as described in the text. For routine culture, human umbilical vein endothelial cells (HUVECs) from pooled donors (TCS Cell Works) were seeded onto 0.1% gelatin-coated plates and cultured in M199 medium supplemented with 20% FBS, 0.1 mg/ml bovine brain endothelial mitogen, 1 ng/ml heparin, and 100 U/ml penicillin streptomycin. HUVECs were used for experiments at passages 4-8. Both B16F0 and LLC cells were cultured in DMEM supplemented with 10% FBS. qRT-PCR RNA was prepared using Trizol (Life Technologies) and cDNA prepared using Quantitech Reverse Transcription Kit (QIAGEN), both as per manufacturer's instructions, using 5, 10, and 20 ng RNA templates to ensure the reaction was quantitative. qPCR was conducted using SyBr green (Quanta) and the Bio-Rad CFX platform, with a 60 C annealing temperature and the primer pairs that are tabulated in the Supplemental Experimental Procedures.
Animal Experimentation
siRNA Transfection iMEFs were transfected with 10 nM collagen II siRNA (L-043139-01-0005 mouse Col2a1 SMARTpool; Dharmacon), or non-targeting siRNA, using the Amaxa Nucleofector system, solution R, program T-20, as per manufacturer's instructions (Lonza). Cells were used for experiments at 48 hr post-transfection.
ECM Generation and Cell Migration
The preparation of cell-derived matrix was performed as previously described [14] , as was time-lapse analysis of cell migration [13] .
AFM
To measure the thickness of ECMs following wound scratch, AFM force spectroscopy and contact imaging were performed using a JPK NanoWizard II Bio AFM in combination with a Bruker MLCT cantilever. A Nanoworld Arrow TL-1 cantilever with bead attached was used for force spectroscopy.
SILAC Mass Spectrometry iMEF-vector and iMEF-tRNA i
Met cells were labeled with light (Arg0/Lys0; Sigma) and heavy amino acids (Arg10/Lys8; Cambridge Isotopes Laboratories). In the case of the forward experiment, iMEF-vector cells were labeled with light amino acids and iMEF-tRNA i Met cells with heavy amino acids, whereas in the reverse experiment, iMEF-vector cells were labeled with heavy amino acids and iMEF-tRNA i Met cells with light amino acids. Briefly, cells were passaged in SILAC DMEM containing light or heavy amino acids supplemented with 10% FBS for three passages and then transferred to media containing light or heavy amino acids supplemented with 10% dialyzed FBS. Cells were cultured for 48 hr at 37 C/5% CO 2 , washed twice with PBS, and transferred into serum-free media for 6 hr at 37 C/5% CO 2 . The media was then acidified to pH 5 with 10% TFA and 10 ml Strataclean beads added per 1 ml media. Beads were collected by brief centrifugation and proteins separated by electrophoresis. Proteins were digested with 0.05 mg/ml trypsin in 50 mM ammonium bicarbonate overnight. Extracted digests were stage tipped and analyzed on a linear trap quadrupole (LTQ)-Orbitrap Elite. Data were searched and quantified against Uniprot MOUSE using MaxQuant [24] .
Tissue Microarray and Immunohistochemistry
The SaPPrOC trial (Clinicaltrials.gov reference NCT01196741) was a randomized phase II study of weekly paclitaxel ± oral saracatinib in women with relapsed, platinum-resistant ovarian cancer. The study was approved by the UK National Research Ethics Service (reference 10/H1211/26), and the primary outcome data are reported elsewhere [25] . A tissue microarray was created with triplicate 5-mm cores from formalin-fixed paraffin-embedded tumor material collected at the time of diagnosis. Five-micrometer sections from formalin-fixed paraffin-embedded tumors were stained for collagen II expression (Dako Autostainer). Stained slides were digitized (Hamamatsu NanoZoomer NDP; Hamamatsu Photonics) and viewed using Slidepath Digital Image Hub V4.0.7 (Leica Microsystems). Areas of tumor were identified and scored using Slidepath Tissue Image Analysis and histoscores generated by multiplying intensity of cellular staining within marked areas (range 0-3) by percentage tumor cells with positive staining (range 0-100), with a maximum histoscore of 300. Data represent mean histoscore per tumor. 
